Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02867592 · OUTCOME

Pharmacokinetics (PK) Parameters of Cabozantinib S-malate: Cmax

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors · Source last updated 2026-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
ng/mL
Interval / dispersion
Standard Deviation
Time frame
Prior to dose, 2, 4, 8 and 20-28 hours after dose on day 1

What was measured

Day 1 PK peak concentration will be summarized by the mean and the standard deviation.

Analysis population: All patients who consented to PK or were required to consent to PK and had enough samples to estimate the PK Parameter of interest.

Groups in this outcome

All Pharmacokinetic Patients

Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Pharmacokinetic Patients15

Reported measurements

Source class 1
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
All Pharmacokinetic Patients567379.0Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        379.0
        value
        567
denoms
  1. counts
    1. group Id
      OG000
      value
      15
    units
    Participants
description
Day 1 PK peak concentration will be summarized by the mean and the standard deviation.
dispersion Type
Standard Deviation
groups
  1. description
    Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    All Pharmacokinetic Patients
param Type
MEAN
population Description
All patients who consented to PK or were required to consent to PK and had enough samples to estimate the PK Parameter of interest.
reporting Status
POSTED
time Frame
Prior to dose, 2, 4, 8 and 20-28 hours after dose on day 1
title
Pharmacokinetics (PK) Parameters of Cabozantinib S-malate: Cmax
type
SECONDARY
unit Of Measure
ng/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice